University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

Syed, N, Coley, HM, Sehouli, J, Koensgen, D, Mustea, A, Szlosarek, P, McNeish, I, Blagden, SP, Schmid, P and Lovell, DP (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res, 71 (9). 3317 - 3327. ISSN 0008-5472

[img]
Preview
PDF
Syed,_Coley_et_al._2011.pdf - Accepted Version
Available under License : See the attached licence file.

Download (1MB)
[img]
Preview
PDF (licence)
SRI_deposit_agreement.pdf

Download (33kB)

Abstract

Resistance to platinum- and taxane-based chemotherapy remains a major clinical impediment to effective management of epithelial ovarian cancer (EOC). To gain insights into resistance mechanisms, we compared gene and confirmed expression patterns of novel EOC cell lines selected for paclitaxel and carboplatin resistance. Here, we report that resistance can be conferred by downregulation of the Polo-like kinase Plk2. Mechanistic investigations revealed that downregulation occurred at the level of transcription via associated DNA methylation of the CpG island in the Plk2 gene promoter in cell lines, primary tumors, and patient sera. Inhibitory RNA (RNAi)-mediated knockdown and ectopic overexpression established a critical functional role for Plk2 in determining apoptotic sensitivity to paclitaxel and carboplatin. In drug-resistant human EOC cell lines, Plk2 promoter methylation varied with the degree of drug resistance and transcriptional silencing of the promoter. RNAi-dependent knockdown of Plk2 abrogated G(2)-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum. Conversely, ectopic expression of Plk2 restored sensitivity to G(2)-M cell-cycle blockade and cytotoxicity triggered by paclitaxel. In clinical cases, DNA methylation of the Plk2 CpG island in tumor tissue was associated with a higher risk of relapse in patients treated postoperatively with carboplatin and paclitaxel (P = 0.003). This trend was also reflected in the analysis of matched serum samples. Taken together, our results implicate Plk2 as a clinically important determinant of chemosensitivity, in support of the candidacy of Plk2 as a theranostic marker to inform EOC management.

Item Type: Article
Additional Information: ©2011 American Association for Cancer Research. This is the author's accepted version.
Uncontrolled Keywords: Carboplatin, Cell Division, Cell Line, Tumor, Cisplatin, CpG Islands, DNA Methylation, Down-Regulation, Drug Resistance, Neoplasm, Female, G2 Phase, Gene Silencing, Humans, Ovarian Neoplasms, Paclitaxel, Protein-Serine-Threonine Kinases, RNA Interference, Transcriptional Activation, Transfection
Divisions: Faculty of Health and Medical Sciences > Biochemistry and Physiology
Depositing User: Symplectic Elements
Date Deposited: 28 Jun 2012 11:46
Last Modified: 23 Sep 2013 19:32
URI: http://epubs.surrey.ac.uk/id/eprint/711383

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800